AI assistant
NeuroPace Inc — Director's Dealing 2024
Feb 6, 2024
33194_dirs_2024-02-06_8f3e7dba-7d43-4f66-ae49-0230c1d52fb1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NeuroPace Inc (NPCE)
CIK: 0001528287
Period of Report: 2024-02-02
Reporting Person: Morrell Martha (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-02 | Common Stock | S | 14143 | $15.0691 | Disposed | 81208 | Direct |
| 2024-02-05 | Common Stock | S | 3446 | $15.1707 | Disposed | 77762 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.285, inclusive. The
reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.